These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35567706)

  • 1. SUMO1 Modification of Tau in Progressive Supranuclear Palsy.
    Takamura H; Nakayama Y; Ito H; Katayama T; Fraser PE; Matsuzaki S
    Mol Neurobiol; 2022 Jul; 59(7):4419-4435. PubMed ID: 35567706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration.
    Martínez-Maldonado A; Ontiveros-Torres MÁ; Harrington CR; Montiel-Sosa JF; Prandiz RG; Bocanegra-López P; Sorsby-Vargas AM; Bravo-Muñoz M; Florán-Garduño B; Villanueva-Fierro I; Perry G; Garcés-Ramírez L; de la Cruz F; Martínez-Robles S; Pacheco-Herrero M; Luna-Muñoz J
    J Alzheimers Dis; 2021; 79(4):1517-1531. PubMed ID: 33459640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
    Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
    J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of tau oligomeric seeds in progressive supranuclear palsy.
    Gerson JE; Sengupta U; Lasagna-Reeves CA; Guerrero-Muñoz MJ; Troncoso J; Kayed R
    Acta Neuropathol Commun; 2014 Jun; 2():73. PubMed ID: 24927818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Arai T; Ikeda K; Akiyama H; Tsuchiya K; Iritani S; Ishiguro K; Yagishita S; Oda T; Odawara T; Iseki E
    Acta Neuropathol; 2003 May; 105(5):489-98. PubMed ID: 12677450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease.
    Camacho J; Rábano A; Marazuela P; Bonaterra-Pastra A; Serna G; Moliné T; Ramón Y Cajal S; Martínez-Sáez E; Hernández-Guillamon M
    Brain Pathol; 2022 Jan; 32(1):e13016. PubMed ID: 34514662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms.
    Sergeant N; Wattez A; Delacourte A
    J Neurochem; 1999 Mar; 72(3):1243-9. PubMed ID: 10037497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuropathology of tauopathy].
    Yoshida M
    Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.
    Cope TE; Rittman T; Borchert RJ; Jones PS; Vatansever D; Allinson K; Passamonti L; Vazquez Rodriguez P; Bevan-Jones WR; O'Brien JT; Rowe JB
    Brain; 2018 Feb; 141(2):550-567. PubMed ID: 29293892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy.
    Zemaitaitis MO; Lee JM; Troncoso JC; Muma NA
    J Neuropathol Exp Neurol; 2000 Nov; 59(11):983-9. PubMed ID: 11089576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
    Vingtdeux V; Davies P; Dickson DW; Marambaud P
    Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofibrillary tangles in progressive supranuclear palsy brains exhibit immunoreactivity to frameshift mutant ubiquitin-B protein.
    Fergusson J; Landon M; Lowe J; Ward L; van Leeuwen FW; Mayer RJ
    Neurosci Lett; 2000 Jan; 279(2):69-72. PubMed ID: 10674623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofibrillary tangles in progressive supranuclear palsy contain the same tau epitopes identified in Alzheimer's disease PHFtau.
    Schmidt ML; Huang R; Martin JA; Henley J; Mawal-Dewan M; Hurtig HI; Lee VM; Trojanowski JQ
    J Neuropathol Exp Neurol; 1996 May; 55(5):534-9. PubMed ID: 8627344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
    Ferrer I; Blanco R; Carmona M; Puig B
    J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process.
    Togo T; Dickson DW
    Acta Neuropathol; 2002 Oct; 104(4):398-402. PubMed ID: 12200627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Stage of Progressive Supranuclear Palsy: A Neuropathological Study of 324 Consecutive Autopsy Cases.
    Nogami A; Yamazaki M; Saito Y; Hatsuta H; Sakiyama Y; Takao M; Kimura K; Murayama S
    J Nippon Med Sch; 2015; 82(6):266-73. PubMed ID: 26823029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human iPSC 4R tauopathy model uncovers modifiers of tau propagation.
    Parra Bravo C; Giani AM; Madero-Perez J; Zhao Z; Wan Y; Samelson AJ; Wong MY; Evangelisti A; Cordes E; Fan L; Ye P; Zhu D; Pozner T; Mercedes M; Patel T; Yarahmady A; Carling GK; Sterky FH; Lee VMY; Lee EB; DeTure M; Dickson DW; Sharma M; Mok SA; Luo W; Zhao M; Kampmann M; Gong S; Gan L
    Cell; 2024 May; 187(10):2446-2464.e22. PubMed ID: 38582079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.
    Nübling G; Schuberth M; Feldmer K; Giese A; Holdt LM; Teupser D; Lorenzl S
    Exp Brain Res; 2017 Aug; 235(8):2407-2412. PubMed ID: 28493068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy.
    Katsuse O; Iseki E; Arai T; Akiyama H; Togo T; Uchikado H; Kato M; de Silva R; Lees A; Kosaka K
    Acta Neuropathol; 2003 Sep; 106(3):251-60. PubMed ID: 12802605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.